Natural and Synthetic Polymer-Based Transdermal Patch Formulation for Bosentan: Development and in vitro Evaluation

Introduction

The goal of this study was to develop and evaluate Bosentan transdermal patches for the treatment of Pulmonary Arterial Hypertension (PAH), which is defined as an abnormally high blood pressure in the arteries that supply blood to the lungs, in patients aged three and up. Patients with PAH may find that bosentan aids their exercise performance and slows the worsening of their symptoms.

Materials and Methods

Using the solvent casting method, Bosentan transdermal patches were made with karaya gum and polyethylene oxide as polymers, PEG 600 as plasticizers and propylene glycol as a permeation enhancer. Folding endurance values for the manufactured Bosentan transdermal patches ranged from 95 to 100, indicating that the patches exhibited good elasticity and flexibility. -p f.

Results and Discussion

The optimized formulation B-10 released 94.77% of the drug for up to 12 hr, according to the drug release trial. Studies using Fourier infrared spectroscopy and differential scanning calorimetry were carried out on the pure drug, polymers and optimised formulation B-10. The results showed that the drug and polymers did not interact with one another. There were no surface cracks or defects in the patches when SEM examination was performed on the pure drug and optimised formulation B-10.